Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | CPB1 | P15086 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9730141 | 0.79 | HCRTR2 (0.44) | HTTSMN1; SMN2L3MBTL1NPC1HCRTR1 | |
| SCHEMBL9187512 | 0.76 | MCL1 (0.44) | HTTEPHX1CES2CES1HTR2A | |
| Acetic Acid SCHEMBL2762930 | 0.75 | HTR2A (0.51) | ALDH1A1NPC1KCNH2HTR2ACPB1 | |
| SCHEMBL25215367 | 0.73 | SMN1; SMN2 (0.38) | SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL324342 | 0.72 | HTR2A (0.56) | ALDH1A1KCNH2HTR2ACPB1MEN1 | |
| SCHEMBL18428493 | 0.72 | HTR2A (0.56) | ALDH1A1KCNH2HTR2ACPB1MEN1 | |
| SCHEMBL40016 | 0.71 | GAA (0.59) | HTTPOLBALDH1A1L3MBTL1MEN1 | |
| SCHEMBL9236592 | 0.71 | ALDH1A1 (0.51) | ALDH1A1 | |
| SCHEMBL11148998 | 0.70 | SLC18A3 (0.42) | KCNH2HTR2ACPB1MEN1KMT2A | |
| SCHEMBL11149002 | 0.70 | KMT2A (0.47) | HTTALDH1A1KCNH2HTR2ACPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361668-B2 | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors | UCB, S.A. (BE) | 2008-04-22 | — | — | US | disclosed |
| US-20050020660-A1 | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors | UCB, S.A. (BE) | 2005-01-27 | — | — | US | disclosed |
| EP-1438309-A1 | QUINUCLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS M2 AND/OR M3 MUSCARINIC RECEPTOR INHIBITORS | UCB, S.A. (BE) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003033495-A1 | QUINUCLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS M2 AND/OR M3 MUSCARINIC RECEPTOR INHIBITORS | UCB, S.A. (BE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020660-A1 | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors | CHRM2, CHRM3, CHRM1 | HTT 4288/4885SMN1; SMN2 2829/4885POLB 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.